Effects of acute and repeated administration of salvinorin a on dopamine function in the rat dorsal striatum

Psychopharmacology

Volumn 197, Issue 3, 2008, Pages 509-517

  Gehrke, Brenda J ^a   Chefer, Vladimir I ^a   Shippenberg, Toni S ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

opioid receptor; Dopamine; Dorsal striatum; No net flux microdialysis; Rat; Salvinorin A

Indexed keywords

COCAINE; DOPAMINE; KAPPA OPIATE RECEPTOR; SALVINORIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; INFUSION; INJECTION; LOCOMOTION; MALE; MICRODIALYSIS; MOLECULAR DYNAMICS; MOLECULAR PROBE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; BRAIN MAPPING; COCAINE; CORPUS STRIATUM; DITERPENES, CLERODANE; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HALLUCINOGENS; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA;

EID: 43149092465     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-1067-6     Document Type: Article

References (39)

1. Acri JB, Thompson AC, Shippenberg T (2001) Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39:343-350
2. Babu K, Boyer EW, Hernor C, Brush DE (2005) Emerging drugs of abuse. Clin Ped Emerg Med 6:81-84
3. Carlezon WA Jr., Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, Rothman RB, Ma Z, Lee DY, Cohen BM (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316:440-447
4. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004) Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious {kappa}-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 308:1197-1203
5. Chefer VI, Shippenberg TS (2006) Paradoxical effects of prodynorphin gene deletion on basal and cocaine-evoked dopaminergic neurotransmission in the nucleus accumbens. Eur J Neurosci 23:229-238
6. Chefer VI, Zakharova I, Shippenberg TS (2003) Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions. J Neurosci 23:3076
7. Chefer VI, Czyzyk T, Bolan EA, Moron J, Pintar JE, Shippenberg TS (2005) Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J Neurosci 25:5029-5037
8. Collins SL, Gerdes RM, D'addario C, Izenwasser S (2001) Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. Behav Pharmacol 12:237-245
9. Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP (1995) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharmacology (Berl) 120:392-399
10. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278
11. Donzanti BA, Althaus JS, Payson MM, Von Voigtlander PF (1992) Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res Commun Chem Pathol Pharmacol 78:193-210
12. Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30-42
13. Ford CP, Mark GP, Williams JT (2006) Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neurosci 26:2788-2797
14. Fuentealba JA, Gysling K, Magendzo K, Andres ME (2006) Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens. J Neurosci Res 84:450-459
15. Glick SD, Maisonneuve IM, Raucci J, Archer S (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res 681:147-152
16. Hazelden Foundation (2004) Drug abuse trends. June 2004. http://www.research.hazelden.org
17. Heidbreder CA, Schenk S, Partridge B, Shippenberg TS (1998) Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 30:255-262
18. Izenwasser S, Acri JB, Kunko PM, Shippenberg T (1998) Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse 30:275-283
19. Olson RJ, Justice JB Jr. (1993) Quantitative microdialysis under transient conditions. Anal Chem 65:1017-1022
20. Pavarin RM (2006) Substance use and related problems: a study on the abuse of recreational and not recreational drugs in Northern Italy. Ann Ist Super Sanita 42:477-484
21. Parsons L, Smith A, Justice J (1991) Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine. Synapse 9:60-65
22. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic, San Diego
23. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233:774-776
24. Ronken E, Mulder AH, Schoffelmeer AN (1993) Interacting presynaptic kappa-opioid and GABAA receptors modulate dopamine release from rat striatal synaptosomes. J Neurochem 61:1634-1639
25. Ronken E, Mulder AH, Schoffelmeer AN (1994) Chronic activation of mu-and kappa-opioid receptors in cultured catecholaminergic neurons from rat brain causes neuronal supersensitivity without receptor desensitization. J Pharmacol Exp Ther 268:595-599
26. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939
27. Rothman RB, Murphy DL, Xu H, Godin JA, Dersch CM, Partilla JS, Tidgewell K, Schmidt M, Prisinzano TE (2007) Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther 320:801-810
28. Schenk S, Partridge B, Shippenberg TS (1999) U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144:339-346
29. Schenk S, Partridge B, Shippenberg TS (2000) Reinstatement of extinguished drug-taking behavior in rats: effect of the kappa-opioid receptor agonist, U69593. Psychopharmacology (Berl) 151:85-90
30. Sheffler DJ, Roth BL (2003) Salvinorin A: the 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107-109
31. Shippenberg TS, Herz A (1987) Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu-and kappa-opioid agonists. Brain Res 436:169-172
32. Shippenberg TS, Bals-Kubik R, Herz A (1993) Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther 265:53-59
33. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53-56
34. Spanagel R, Herz A, Shippenberg T (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046-2050
35. Thompson AC, Zapata A, Justice JB Jr., Vaughan RA, Sharpe LG, Shippenberg TS (2000) {kappa}-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci 20:9333-9340
36. Valdes LJ III (1994) Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A. J Psychoactive Drugs 26:277-283
37. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DY, Huang P, Li JG, Cowan A, Liu-Chen LY (2005) Comparison of pharmacological activities of three distinct kappa ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-230
38. You ZB, Herrera-Marschitz M, Terenius L (1999) Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Ther 290:1307-1315
39. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) 179:551-558